Singapore markets closed
  • Straits Times Index

    +5.85 (+0.19%)
  • Nikkei

    -54.25 (-0.19%)
  • Hang Seng

    +242.68 (+0.85%)
  • FTSE 100

    -135.96 (-1.90%)

    -236.28 (-0.65%)
  • CMC Crypto 200

    -51.42 (-5.47%)
  • S&P 500

    -55.41 (-1.31%)
  • Dow

    -533.37 (-1.58%)
  • Nasdaq

    -130.97 (-0.92%)
  • Gold

    -10.90 (-0.61%)
  • Crude Oil

    +0.46 (+0.65%)
  • 10-Yr Bond

    -0.0610 (-4.04%)
  • FTSE Bursa Malaysia

    +18.19 (+1.16%)
  • Jakarta Composite Index

    -61.33 (-1.01%)
  • PSE Index

    -36.54 (-0.53%)

Shareholder Alert: Robbins LLP Reminds Investors MEI Pharma, Inc. (MEIP) Accused of Misleading Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.

Shareholder rights law firm Robbins LLP reminds investors that a purchaser of MEI Pharma, Inc. (NASDAQ: MEIP) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 2, 2017 and July 1, 2020. MEI Pharma is a late-stage pharmaceutical company that focuses on the development of various therapies for the treatment of cancer. One of MEI Pharma's drug candidates include Pracinostat, an oral histone deacetylase ("HDAC") inhibitor.

If you suffered a loss due to MEI Pharma's misconduct, click here.

MEI Pharma, Inc. (MEIP) Accused of Misleading Shareholders

According to the complaint, in 2016 MEI Pharma entered into an exclusive license agreement with Helsinn Healthcare SA, a Swiss pharmaceutical corporation ("Helsinn"), in which Helsinn would develop, manufacture, and commercialize Pracinostat while MEI Pharma received $20 million for the grant rights with the potential to receive up to $444 million in regulatory and sales-based milestones along with royalty payments. In August 2017, MEI Pharma and Helsinn announced the beginning of the Phase 3 Pracinostat trial after "the potential of [P]racinostat … was demonstrated in the Phase 2 study," touting that the "well-powered, rigorously designed Phase 3 study" would bring Pracinostat one step closer to becoming a treatment for those with AML. In later SEC reports and filings, MEI Pharma continued to tout the "potency" and median overall survival of patients in the Phase 2 trial of Pracinostat. Despite the Company's positive representations of the drug, on July 2, 2020, MEI Pharma announced it was discontinuing the Phase 3 Pracinostat trial, revealing that an interim futility analysis of the study "demonstrated [Pracinostat] was unlikely to meet the primary endpoint of overall survival compared to the control group." On this news, MEI Pharma's shares fell 18% to close at $3.49 per share and has yet to recover.

MEI Pharma, Inc. (MEIP) Shareholders Have Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against MEI Pharma settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on


Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
(800) 350-6003

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting